Document is current
Any future updates will be listed below
-
Authors
Binder, Moritz
Szalat, Raphael E.
Talluri, Srikanth
Fulciniti, Mariateresa https://orcid.org/0000-0002-1432-9742
Avet-Loiseau, Hervé
Parmigiani, Giovanni
Samur, Mehmet K. https://orcid.org/0000-0002-9978-5682
Munshi, Nikhil C. https://orcid.org/0000-0002-7344-9795
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01-155258, 5P50 CA100707)
U.S. Department of Health & Human Services | National Institutes of Health
Department of Veterans Affairs | Office of Academic Affiliations, Department of Veterans Affairs (I01BX001584-01)
- License Information
-
More Information
Article History
Received: 6 January 2023
Accepted: 12 April 2024
First Online: 16 May 2024
Competing interests
: N.C.M. is a consultant for BMS, Janssen, Oncopep, Amgen, Pfizer, Karyopharm, Legend, NextRNA, Raqia, Abbvie, Takeda, and GSK, and on the board of directors of Oncopep. G.P. is a co-founder of Phaeno Biotechnologies, serves on the Scientific Advisory Board of Konica Minolta Healthcare Americas and consults with Foundation Medicine and Delfi Diagnostics. The remaining authors declare no competing interests.
